Not surprisingly, most pharma and biotech companies are pursuing hematological cancers by targeting lymphocyte restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123. The gene discussed is TNFRSF17; the disease is hematopoietic and lymphoid cell neoplasm.